2024
Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Jansen C, Pagadala M, Cardenas M, Prabhu R, Goyal S, Zhou C, Chappa P, Vo B, Ye C, Hopkins B, Zhong J, Klie A, Daniels T, Admassu M, Green I, Pfister N, Neill S, Switchenko J, Prokhnevska N, Hoang K, Torres M, Logan S, Olson J, Nduom E, del Balzo L, Patel K, Burri S, Asher A, Wilkinson S, Lake R, Kesarwala A, Higgins K, Patel P, Dhere V, Sowalsky A, Carter H, Khan M, Kissick H, Buchwald Z. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates. Nature Communications 2024, 15: 8854. PMID: 39402027, PMCID: PMC11473782, DOI: 10.1038/s41467-024-53034-6.Peer-Reviewed Original ResearchConceptsPre-operative stereotactic radiosurgeryCD8 T cellsEffector-like cellsT cellsStereotactic radiosurgeryBrain metastasesCD8 T cell responsesEndpoint of overall survivalDistant brain failureResected brain metastasesEfficacy of immunotherapyT cell responsesAntigen presenting cellsSecondary clinical endpointsLocal recurrenceLeptomeningeal diseaseOverall survivalImmune compositionProspective trialsImmune nichePrimary endpointImmunological correlatesPresenting cellsClinical outcomesPilot study
2022
CD8 T cell activation in cancer is comprised of two distinct phases
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Jansen C, Master V, Sanda M, Kissick H. CD8 T cell activation in cancer is comprised of two distinct phases. The Journal Of Immunology 2022, 208: 121.09-121.09. DOI: 10.4049/jimmunol.208.supp.121.09.Peer-Reviewed Original ResearchStem-like CD8 T cellsCD8 T cellsTumor-draining LNCD8 T cell activationT cellsT cell activationCo-stimulationLCMV-GPTumor-specific CD8 T cellsT cell responses to tumorsHeterogeneous T-cell subsetsCD8 T cell differentiationAutologous dendritic cellsProstate cancer modelResponse to tumorsT cell subsetsAntigen presenting cellsCo-stimulatory signalsTumor-bearing miceT cell differentiationStem-like phenotypeDifferentiation ex vivoCD8 responsesEffector phenotypeDendritic cells
2021
658 CD8 T cell activation in cancer is comprised of two distinct phases
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Jansen C, Master V, Sanda M, Kissick H. 658 CD8 T cell activation in cancer is comprised of two distinct phases. Journal For ImmunoTherapy Of Cancer 2021, 9: a686-a686. DOI: 10.1136/jitc-2021-sitc2021.658.Peer-Reviewed Original ResearchTumor-draining lymph nodesCD8 T cell activationCD8 T cellsStem-like CD8 T cellsT cell activationResponse to tumorsT cellsCo-stimulationEffector programTumor-specific CD8 T cellsImmune response to tumorsSubsets of CD8 T cellsModel of T cell differentiationActivated CD8 T cellsProstate cancer mouse modelCD8 T cell biologyCancer mouse modelAntigen presenting cellsT cell differentiationT cell biologyStem-like cellsAutologous tumorCD8 infiltrationCD8 subsetsEffector phenotypeAbstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases
Jansen C, del Balzo L, Prabhu R, Logan S, Chappa P, Patel K, Wilkinson S, Lake R, Shu H, Zhong J, Dhere V, Olson J, Sowalsky A, Khan M, Kissick H, Buchwald Z. Abstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases. Clinical Cancer Research 2021, 27: po-041-po-041. DOI: 10.1158/1557-3265.radsci21-po-041.Peer-Reviewed Original ResearchCD8+ T cellsStem-like CD8+ T cellsNon-small cell lung cancer brain metastasisNon-small cell lung cancerAntigen presenting cellsLung cancer brain metastasisStereotactic radiosurgeryBrain metastasesCancer brain metastasesImmune nicheT cellsPresenting cellsMHC-II+TCF-1CD8+ T cell infiltrationImmunological nichePost-operative stereotactic radiosurgeryPre-operative stereotactic radiosurgeryT cell infiltrationCell lung cancerCohort of patientsCheckpoint blockadePD-1Disease recurrenceGenitourinary malignancies